Avidity Biosciences/$RNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avidity Biosciences
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Ticker
$RNA
Sector
Primary listing
Employees
391
Headquarters
Website
RNA Metrics
BasicAdvanced
$5.8B
-
-$3.57
0.95
-
Price and volume
Market cap
$5.8B
Beta
0.95
52-week high
$51.40
52-week low
$21.51
Average daily volume
4M
Financial strength
Current ratio
9.259
Quick ratio
8.823
Long term debt to equity
0.101
Total debt to equity
0.431
Profitability
EBITDA (TTM)
-518.735
Gross margin (TTM)
-3,725.48%
Net profit margin (TTM)
-4,247.76%
Operating margin (TTM)
-4,863.29%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-24.01%
Return on equity (TTM)
-37.76%
Valuation
Price to revenue (TTM)
477.035
Price to book
4.06
Price to tangible book (TTM)
4.06
Price to free cash flow (TTM)
-10.181
Free cash flow yield (TTM)
-9.82%
Free cash flow per share (TTM)
-3.935
Growth
Revenue change (TTM)
1.23%
Earnings per share change (TTM)
21.65%
3-year revenue growth (CAGR)
10.33%
3-year earnings per share growth (CAGR)
4.45%
What the Analysts think about RNA
Analyst ratings (Buy, Hold, Sell) for Avidity Biosciences stock.
Bulls say / Bears say
Novartis is exploring an acquisition of Avidity, driving its shares up 23% to $47.10 and highlighting significant strategic interest in its rare-disease pipeline (Reuters )
Avidity is advancing three clinical-stage RNA conjugate programs—targeting DM1, DMD, and FSHD—offering multiple pipeline catalysts and diversification in rare muscle disorders (FT )
Del-zota for Duchenne muscular dystrophy has secured FDA accelerated approval status, positioning it for expedited review and potential first-mover advantage in its indication (FT )
M&A discussions are still in preliminary stages and could collapse or attract rival bids, potentially triggering a sharp sell-off if a takeover by Novartis does not materialize (Reuters )
The pipeline consists of early to mid-stage candidates—Del-zota and two other AOCs still in initial clinical trials—leaving valuation vulnerable to any negative trial or regulatory outcomes (Reuters )
Pharmaceutical deal-making is under scrutiny amid political risk and potential pricing policy changes, which could hinder Avidity’s ability to secure favorable partnerships or pricing for future products (FT )
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
RNA Financial Performance
Revenues and expenses
RNA Earnings Performance
Company profitability
RNA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avidity Biosciences stock?
Avidity Biosciences (RNA) has a market cap of $5.8B as of September 18, 2025.
What is the P/E ratio for Avidity Biosciences stock?
The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of September 18, 2025.
Does Avidity Biosciences stock pay dividends?
No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Avidity Biosciences dividend payment date?
Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Avidity Biosciences?
Avidity Biosciences (RNA) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.